Key Points
- Draig Therapeutics has completed an oversubscribed $65 million Series B financing round.
- The round was led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences.
- The company said the funding will support development of its pipeline of medicines for neuropsychiatric disorders, including depression.
- The money will particularly help advance DT-101, Draig’s lead drug candidate for major depressive disorder.
- Draig said DT-101 has shown encouraging safety, tolerability and target engagement data in early work.
- The company described the financing as a step that strengthens its clinical development plans in mental health research.
Cardiff (Cardiff Daily) August 4, 2026 – Draig Therapeutics has announced that it has closed an oversubscribed $65 million Series B funding round, money the company says will be used to push forward its work on treatments for mental health conditions, including major depressive disorder.
The company is a clinical-stage biopharmaceutical business developing neuropsychiatric therapies, and the new financing was led by Deep Track Capital. The company added that the round also included support from Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences.
Why is the funding significant?
The central purpose of the new funding is to help Draig move its drug pipeline further through development, with DT-101 at the centre of that effort. Draig says the candidate is being developed for major depressive disorder, which the company described as one of the largest unmet needs in medicine.
Dr Ivana Magovčević-Liebisch, President and Chief Executive Officer of Draig Therapeutics, said the company’s “next-generation AMPA receptor modulator, DT-101, has shown encouraging safety, tolerability and target engagement data,” and that has given the company “real conviction in its potential.” That statement places the company’s immediate focus on continuing clinical development rather than on broader commercial claims.
What is DT-101 designed to do?
DT-101 is Draig’s lead candidate and is being developed as a next-generation AMPA receptor modulator for major depressive disorder. The company’s wider programme aims to address neuropsychiatric disorders by targeting brain signalling pathways linked to mood and related conditions.
The company is using the new capital to support mid-stage testing of the candidate, while Draig’s pipeline information says TARIAN-1 is a global, randomised, double-blind, placebo-controlled Phase 2 trial evaluating the efficacy, safety and tolerability of DT-101 in people with MDD. That trial has already been initiated in the United States, with further initiations planned in the UK and EU in 2026, according to the company.
What have the company and reports said about progress?
Draig’s statement says the funding will support further development of its pipeline, while the company’s published pipeline material indicates DT-101 has already advanced into Phase 2 evaluation. The company has said the trial is measuring change in participants’ Montgomery Åsberg Depression Rating Scale score as the primary endpoint.
Draig’s leadership believes DT-101 has “best-in-disease potential” for major depressive disorder, although that is the company’s own assessment rather than a confirmed clinical outcome. The available company material shows that the programme remains in development and has not yet produced late-stage or approved-treatment results.
Who is backing the round?
The funding round was led by Deep Track Capital. Other participants named by Draig were Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences.
This investor mix suggests the company has attracted support from a combination of specialist healthcare investors and broader financial backers, but the public statement does not provide a detailed breakdown of individual commitments. The announcement also did not disclose a valuation, which means the market cannot yet measure the round against a new pricing benchmark.
What does this mean for mental health drug development?
The funding gives Draig more room to continue clinical work on a treatment aimed at depression and other neuropsychiatric disorders. In practical terms, that means the company should be better placed to run trials, gather safety and efficacy data, and decide whether DT-101 can move further along the development path.
Major depressive disorder remains a high-burden condition, and Draig is positioning DT-101 as a candidate that works through a different mechanism from more familiar antidepressant approaches. However, the available material still reflects an ongoing development programme, not a proven treatment outcome.
Background of the development
Draig Therapeutics is a Cardiff University spin-out focused on neuropsychiatric medicines. Earlier reporting said the company emerged from stealth with $140 million in Series A funding, and that DT-101 was already being advanced into clinical testing after earlier safety work.
The company’s July 2026 financing adds to that earlier capital base and raises its total funding to about $205 million. This latest round therefore appears to be part of a broader strategy to keep the company funded through clinical development rather than a one-off fundraising event.
Explore More Local Cardiff News
Marshfield fire disrupts Newport trains, Wales 2026
Cardiff Roads Return to 30mph After 20mph Review | Cardiff 2026
Prediction: how could this affect patients and the sector?
For patients with major depressive disorder, the immediate effect is indirect: the funding may help keep a possible new treatment moving through trials, but it does not guarantee approval or access. For the wider mental health sector, the round suggests investor interest remains strong in neuroscience companies pursuing alternative mechanisms for depression.
For clinicians, researchers and investors, the next meaningful signal will be data from the ongoing DT-101 studies, because that is what will show whether the early safety and target-engagement findings translate into real clinical benefit. If the programme progresses successfully, it could strengthen confidence in AMPA receptor modulation as a treatment strategy; if it does not, the funding will still have supported another careful test of that idea.
